SAN DIEGO, September 29, 2015 /PRNewswire/ --Regen BioPharma, Inc. Announces :Cancer Stem Cell Gene Target Shown to be a Key Mediator of Cancer Immune Surveillance by Independent Researchers - (Company anticipates its small molecule discovery program can be used to Promote anti-tumor immunity)
Their Cache of New Drug Treatment Protocols/Products will elevate Regen to the Forefront of Stem Cell Research and treatment for the Diseases and Disorders aforementioned above. It could also lead to outside interest from much larger companies with the end result of a Merger or Buyout. Keep in mind Chief Scientific Director-Thomas Ichim PhD was the CEO of Medi Stem and instrumental, leading the way for them being Bought Out by Intrexeron for $26 Million.
With this recent News Regen is at a price level that is most advantageous for New Investors, and a great average down opportunity for those who hold a position.
We believe Regen is a LONG PLAY a Great Opportunity for those looking for a company dedicated to continued research and development of New Drugs/Products that one day will be the leader in this sector. Perhaps someday not only Treating, but possibly finding a Cure for the debilitating and fatal diseases that plague the world today.
There is also Short Term GAIN/Profit potential as was witnessed not long ago when Regen spiked 70% or so recently.
For Due Diligence and Research Visit:
Q3-Third Quarter Review Coming Soon for RGBP !!
Disclosure: I/we have no positions in any stocks mentioned, and no plans to initiate any positions within the next 72 hours.